With roughly half of its 13-strong biosimilar pipeline comprising in-licensed assets, Teva insists that its partnerships in the space are not dilutive to its margins. They “can compete with traditional generics,” the Israeli firm maintains, and can “match the overall margin we have.”
Teva management has spoken at length about the firm’s incentives to maintain and drive its margins amid continued flatness for its top line